Medicaid and CHIP Halt Coverage of Hormone Therapy and Gender Transition Surgery for Minors

From the official announcement by CMS / HHS ↗

The Centers for Medicare and Medicaid Services (CMS), part of the Department of Health and Human Services (HHS), announced an end to the use of federal Medicaid and CHIP funds to pay for puberty blockers, cross-sex hormones, and gender transition surgeries in children and adolescents. These are two public health insurance programs for low-income individuals and children ineligible for Medicaid whose families cannot afford private insurance. According to CMS, the decision is based on a review of research studies both domestic and international, including the Cass Review from England, concluding that evidence supporting the clinical benefits of these interventions in children remains insufficient.

The final rule will take effect on October 13, 2026. Children receiving hormone treatment at that time will continue to be covered by Medicaid and CHIP for a maximum of six months for dose reduction, according to CMS's announcement. HHS Secretary Robert F. Kennedy Jr. stated that the administration is ending the use of federal tax dollars to fund "sex-rejecting" procedures in children, emphasizing that these interventions carry serious risks and may cause irreversible harm, and that the federal government will no longer use Medicaid and CHIP funds to pay for procedures that do not meet required evidence standards. CMS Director Dr. Mehmet Oz described these procedures as "experimental" and "life-altering," arguing that there is insufficient clear evidence of benefit.

This policy affects only the federal budget portion of Medicaid and CHIP, does not prohibit states from using their own budgets to continue coverage if they choose. Directly affected are families with children currently receiving or about to begin gender hormone therapy, particularly those relying on Medicaid or CHIP due to low income — including many Vietnamese-American families in areas such as Houston and Orange County who rely on these programs for their children. Mental health services, including treatment for gender dysphoria, are not included in the cuts and remain covered by Medicaid and CHIP under current EPSDT regulations, according to CMS documentation.

The medical community is divided on this decision. The American Academy of Pediatrics opposes the government's restriction on this type of care, arguing that treatment decisions should be made by patients, families, and physicians. Readers can view the full official announcements from CMS and HHS at the source links below.

Analysis

This rule is among a series of actions by the current administration aimed at restricting gender-related health care for adolescents, following President Donald Trump's previous characterization of funding for these surgeries as "barbaric" and linking the issue to the November midterm elections. CMS relies heavily on the Cass Review from England, which has also generated controversy within the American medical community because its conclusions differ from the longstanding clinical guidelines of pediatric professional associations. Because this is a final rule rather than a draft, the next typical step — a period of public comment — appears to have been completed before announcement; what remains uncertain is the likelihood of legal challenges, as has occurred with many other controversial federal policies.

Diaspora Impact

Families with children currently receiving puberty blockers or cross-sex hormones through Medicaid or CHIP should contact their state Medicaid office before October 13, 2026 to understand how the six-month transition period will apply to their child's specific situation. Because the rule limits only the federal budget portion, some states may continue using their own funds to maintain coverage — parents should ask their state Medicaid agency directly, rather than going through intermediaries. Mental health services related to gender care are not affected and will continue to be covered as before.